A. P. Holmes

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.

F. Martinez, R. Brook, B. Celli, 2017, Respiratory medicine.

Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial.

F. Martinez, P. Calverley, R. Brook, 2018, American journal of respiratory and critical care medicine.

Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial.

F. Martinez, P. Calverley, R. Brook, 2018, American journal of respiratory and critical care medicine.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

E. Perez, R. Gelber, J. Baselga, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)

R. Gelber, J. Baselga, Bing-he Xu, 2013 .

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS).

G. Kapoor, S. Schuetze, B. V. Van Tine, 2022, Journal of Clinical Oncology.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.

G. Kapoor, S. Schuetze, N. Somaiah, 2021 .